News

»News
News 2018-02-06T21:22:56+00:00
Eiger BioPharmaceuticals to Participate in Two Upcoming Investor Conferences in February

PALO ALTO, Calif. – February 6, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate overview and business update at two upcoming conferences in February.

  • 2018 BIO CEO & Investor Conference, February 12, 2018 at 3:00 pm ET at the New York Marriott Marquis in New York City. Eiger will host one-on-one meetings.
  • BTIG 5th Annual Healthcare Conference, February 26-28, 2018 in Snowbird, UT. Eiger will host one-on-one meetings.

A live webcast of the BIO CEO presentation will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the “Investors” tab. A replay of the webcast will be available approximately one hour following the completion of the live event.

About Eiger
Eiger is a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for orphan diseases.  We are committed to translational innovation and the development of well-characterized drugs acting on newly identified or novel targets.  Our mission is to systematically reduce the time and cost of the drug development process to more rapidly deliver important medicines to patients with orphan diseases.  For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Eiger BioPharmaceuticals

SOURCE Eiger BioPharmaceuticals, Inc.
Investors: Ingrid Choong, PhD
Email: ichoong@eigerbio.com
Phone: 1-650-619-6115

PDF Icon

DateTitle (click to view the full PR)PDF
November 13, 2017Eiger BioPharmaceuticals to Present at Jefferies 2017 Healthcare ConferencePDF Icon
November 9, 2017Eiger BioPharmaceuticals Reports Third Quarter 2017 Financial ResultsPDF Icon
November 6, 2017Eiger BioPharmaceuticals to Participate in Upcoming Investor ConferencesPDF Icon
October 31, 2017Eiger BioPharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise In Full of Underwriter’s Option to Purchase Additional SharesPDF Icon
October 27, 2017Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common StockPDF Icon
October 26, 2017Eiger BioPharmaceuticals Announces Proposed Public Offering of Common StockPDF Icon
October 23, 2017Eiger Announces Positive Phase 2 Interim 24-Week Data with Pegylated Interferon Lambda in Hepatitis Delta Virus (HDV) Infection at the American Association for the Study of Liver Diseases (AASLD) MeetingPDF Icon
October 2, 2017Eiger Announces Abstracts and Presentations at the American Association for the Study of Liver Diseases (AASLD) MeetingPDF Icon
September 18, 2017Eiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of DirectorsPDF Icon
September 5, 2017Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus InfectionPDF Icon
August 30, 2017Eiger BioPharmaceuticals to Present at Two Upcoming Investor ConferencesPDF Icon
August 14, 2017Eiger BioPharmaceuticals Reports Second Quarter 2017 Financial ResultsPDF Icon
August 8, 2017Eiger BioPharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference on August 16thPDF Icon
July 27, 2017Eiger Announces FDA Fast Track Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus InfectionPDF Icon
July 24, 2017Eiger Completes Enrollment in Phase 2 LIMT HDV Study of Pegylated Interferon Lambda in Hepatitis Delta Virus InfectionPDF Icon
June 14, 2017Eiger BioPharmaceuticals Announces Sale of Non-Strategic Assets to Theragene PharmaceuticalsPDF Icon
June 14, 2017Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of DirectorsPDF Icon
June 12, 2017Eiger Reports Additional Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients at American Diabetes Association Meeting in San DiegoPDF Icon
June 6, 2017Eiger Completes Enrollment in Phase 2 Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia PatientsPDF Icon
May 30, 2017Eiger BioPharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference June 7thPDF Icon
May 17, 2017Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental LymphedemaPDF Icon
May 15, 2017Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial HypertensionPDF Icon
May 12, 2017Eiger BioPharmaceuticals Reports First Quarter 2017 Financial ResultsPDF Icon
May 8, 2017Eiger Announces Presentation of Prevalence Data of Hepatitis Delta Virus (HDV) Infection in the U.S. at Digestive Disease Week (DDW) in ChicagoPDF Icon
May 4, 2017Eiger BioPharmaceuticals to Host Key Opinion Leader Event Addressing Need for Novel Mechanisms in the Treatment of Pulmonary Arterial Hypertension (PAH) on May 10th in New York City – Phase 2 LIBERTY Study Update for Ubenimex in PAHPDF Icon
May 3, 2017Eiger Announces U.S. IND Filing of Pegylated Interferon Lambda for Hepatitis Delta Virus Infection – LIMT HDV: Lambda Interferon MonoTherapy in HDV Study EnrollingPDF Icon
April 24, 2017Eiger Announces Abstract and Presentation at 2017 Digestive Disease Week in ChicagoPDF Icon
April 21, 2017Eiger Announces Additional Phase 2 Clinical Trial Results for Lonafarnib at The International Liver Congress™ 2017PDF Icon
April 18, 2017Eiger Announces Industry Veteran Lisa Porter, MD to Lead Development of Exendin 9-39 for the Treatment of Post-Bariatric Hypoglycemia – Novel Liquid Formulation of Exendin 9-39 AdvancingPDF Icon
April 6, 2017Eiger Announces Abstracts and Presentations of LOWR HDV Program at the European Association for the Study of the Liver (EASL) MeetingPDF Icon
March 23, 2017Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial ResultsPDF Icon
January 31, 2017Eiger BioPharmaceuticals to Present at BIO CEO & Investor Conference February 13th and Participate in SunTrust Robinson Humphrey Orphan Drug Day Conference February 14thPDF Icon
January 3, 2017Eiger Completes $25 Million Debt Financing with Oxford FinancePDF Icon
January 3, 2017Eiger Announces First Patient Dosed in Open-Label Extension of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension (PAH)— First-in-class inhibitor of LTB4 targeting disease modification in PAHPDF Icon
DateTitle (click to view the full PR)PDF
December 12, 2016Eiger Announces Multiple Advances in Exendin 9-39 Program for the Treatment of Post-Bariatric Hypoglycemia (PBH) – Positive Interim Data from Phase 2 Multiple-Ascending Dose Study – Novel Liquid Formulation of Exendin 9-39 – US Orphan Designation for Hyperinsulinemic HypoglycemiaPDF Icon
November 29, 2016Eiger Updates Progress in Clinical Development Program for Exendin 9-39 to Treat Post-Bariatric Hypoglycemia (PBH) – Exendin 9-39 investigational new drug (IND) application filed – PBH Analyst / Key Opinion Leader Event planned December 9th – Multiple-ascending dose (MAD) study interim data to be presentedPDF Icon
November 14, 2016Eiger Announces Additional LOWR HDV Program Data, Clinical and Regulatory Plans at the American Association for the Study of Liver Diseases (AASLD) Meeting – Update on Data Presented and Analyst Meeting through Monday EveningPDF Icon
November 14, 2016Eiger Announces Positive Phase 2 Data at the American Association for the Study of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified with Lonafarnib Therapy in LOWR HDV Program – Data Presented through Monday MorningPDF Icon
November 8, 2016Eiger BioPharmaceuticals Reports Third Quarter 2016 Financial ResultsPDF Icon
October 24, 2016Eiger BioPharmaceuticals Launches Nationwide Hepatitis Delta Virus (HDV) Campaign to Expand Awareness and Testing for HDV Infection – Collaboration with ARUP Laboratories and Hepatitis B Foundation – HDV viral load assay now available in U.S.PDF Icon
October 19, 2016Eiger Announces First Patient Dosed in Phase 2 Study of Pegylated Interferon Lambda in Hepatitis D Virus (HDV) Infection – LIMT HDV: Lambda Interferon MonoTherapy in HDV StudyPDF Icon
October 17, 2016Eiger Announces Orphan Designation of Exendin 9-39 for Treatment of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) from European Medicines Agency (EMA)PDF Icon
October 13, 2016Eiger Announces Abstracts and Presentations of LOWR HDV Program at the American Association for the Study of Liver Diseases (AASLD) MeetingPDF Icon
September 7, 2016Eiger Announces Completion of Dosing in Phase 2 LOWR HDV – 4 Study at Hannover Medical SchoolPDF Icon
September 6, 2016Eiger BioPharmaceuticals to Present at the BioCentury NewsMakers in the Biotech Industry Conference on September 9thPDF Icon
September 1, 2016Eiger BioPharmaceuticals to Present at the 5th Annual Liolios Gateway Conference on September 7, 2016PDF Icon
August 18, 2016Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common StockPDF Icon
August 17, 2016Eiger BioPharmaceuticals Announces Proposed Public Offering of Common StockPDF Icon
August 10, 2016Eiger BioPharmaceuticals Reports Second Quarter 2016 Financial ResultsPDF Icon
July 28, 2016Eiger BioPharmaceuticals Announces Partnership with the Hepatitis B Foundation – Raising Awareness of Hepatitis Delta Virus Co-InfectionPDF Icon
July 25, 2016Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 ULTRA Study of Ubenimex in Secondary LymphedemaPDF Icon
July 20, 2016Eiger BioPharmaceuticals Announces Completion of Dosing in Phase 2 LOWR HDV – 3 Study at National Institutes of Health (NIH)PDF Icon
July 18, 2016Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial HypertensionPDF Icon
July 6, 2016Eiger BioPharmaceuticals to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference on July 12thPDF Icon
June 13, 2016Eiger Announces Positive Clinical Results of Single Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Post-Bariatric HypoglycemiaPDF Icon
June 6, 2016Eiger to Participate in Jefferies 2016 Healthcare ConferencePDF Icon
May 10, 2016Eiger Announces First Patient Dosed in Phase 2 Multiple Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Hypoglycemia Post-Gastric Bypass SurgeryPDF Icon
May 3, 2016Eiger Bio Strengthens Senior Management Team with Announcement of Debra Odink, PhD as Senior Vice President of Technical OperationsPDF Icon
April 20, 2016Eiger BioPharmaceuticals Announces License of Worldwide Rights to Pegylated Interferon Lambda-1a from Bristol-Myers SquibbPDF Icon
April 4, 2016Eiger BioPharmaceuticals Strengthens Board of Directors with Addition of Industry Veteran Charles J. “Chuck” BramlagePDF Icon
March 30, 2016Eiger BioPharmaceuticals Announces Abstracts and Presentations of Lonafarnib Data in Hepatitis Delta at the European Association for the Study of the Liver (EASL) MeetingPDF Icon
March 28, 2016Eiger BioPharmaceuticals Granted Orphan Medicinal Product Designation for Ubenimex in Pulmonary Arterial Hypertension by European Medicines AgencyPDF Icon
March 22, 2016Eiger BioPharmaceuticals Closes Merger With Celladon Renamed Eiger and New Trading Symbol (NASD: EIGR, as of March 23) Developing a Clinical Stage Pipeline of Orphan Disease ProgramsPDF Icon
March 22, 2016Celladon Announces Results of Special MeetingPDF Icon
March 14, 2016Eiger Announces Completion of Enrollment of Phase 2 LOWR HDV – 4 (LOnafarnib With Ritonavir in Hepatitis Delta Virus – 4) Study at Hannover Medical SchoolPDF Icon
March 9, 2016ISS and Glass Lewis Recommend Celladon Corporation Shareholders Vote “FOR” Proposed MergerPDF Icon
February 29, 2016Eiger to Participate in Cowen & Company 2016 Health Care ConferencePDF Icon
February 11, 2016Celladon Sets Date for Special Meeting of StockholdersPDF Icon
January 19, 2016Eiger BioPharmaceuticals Announces Completion of Enrollment of Phase 2 LOWR HDV – 3 (LOnafarnib With Ritonavir in Hepatitis Delta Virus – 3) Study at National Institutes of Health (NIH)PDF Icon
January 6, 2016Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LOWR HDV – 4 (LOnafarnib With Ritonavir in Hepatitis Delta Virus – 4) Study at Hannover Medical School in Hannover, GermanyPDF Icon
DateTitle (click to view the full PR)PDF
December 15, 2015Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering Bestatin™ (Ubenimex) for the Treatment of Pulmonary Arterial HypertensionPDF Icon
November 30, 2015Eiger BioPharmaceuticals Granted Orphan Drug Status for Ubenimex in Pulmonary Arterial HypertensionPDF Icon
November 18, 2015Eiger BioPharmaceuticals and Celladon Corporation Sign Merger Agreement PDF Icon
November 12, 2015Eiger BioPharmaceuticals Announces Acquisition of Exclusive License to Program for Treatment of Post-Bariatric Hypoglycemia from Stanford University – Clinical Proof of Concept Data Already Generated in PatientsPDF Icon
November 11, 2015Eiger BioPharmaceuticals Announces Acquisition of Exclusive License to Lymphedema Program from Stanford University – Novel Target Identified as Potential Therapeutic Approach for LymphedemaPDF Icon
November 10, 2015Eiger BioPharmaceuticals Announces Acquisition of Exclusive License to Pulmonary Arterial Hypertension (PAH) Program from Stanford UniversityPDF Icon
November 9, 2015Eiger BioPharmaceuticals Announces License Agreement with Nippon Kayaku to Develop Bestatin™ (ubenimex) for Inflammatory Diseases Involving LTB4 – First Clinical Target – Pulmonary Arterial Hypertension (PAH)PDF Icon
October 23, 2015Eiger BioPharmaceuticals Appoints Thomas J. Dietz, Ph.D. to the Eiger Board of DirectorsPDF Icon
October 20, 2015Eiger BioPharmaceuticals Appoints Eduardo Martins, M.D., D.Phil., as Senior Vice President, Liver and Infectious Diseases Drug DevelopmentPDF Icon
August 17, 2015Eiger BioPharmaceuticals Announces Key Operational Hires to Senior Management Team: Jim Welch, Chief Financial Officer & Jim Shaffer, Chief Business OfficerPDF Icon
July 20, 2015The Lancet Infectious Diseases Journal Publishes Results of Phase 2 Study of Lonafarnib in Hepatitis Delta Virus (HDV) Infected PatientsPDF Icon
April 28, 2015Eiger BioPharmaceuticals Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV)PDF Icon
April 20, 2015FDA Grants Fast Track Designation to Eiger Bio’s Lonafarnib for Hepatitis Delta Virus (HDV) InfectionPDF Icon
April 14, 2015Eiger BioPharmaceuticals Announces Senior Staff Appointments in Clinical Development and Regulatory Affairs: Dr. Joanne Quan, M.D., as Chief Medical Officer & Dr. Shelly Xiong, Ph.D., as Vice President of Regulatory AffairsPDF Icon
April 13, 2015Eiger BioPharmaceuticals Announces Abstracts and Presentations of Lonafarnib Data in Hepatitis Delta (HDV) at the European Association for the Study of the Liver Conference – April 22 to 26, 2015PDF Icon
February 23, 2015Eiger BioPharmaceuticals Announces Presentation of Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib – NIH Principal Investigator to Present Abstract and Poster at Conference on Retroviruses and Opportunistic Infections (CROI)PDF Icon